-
Changing Cancer Research: Biden Cancer Initiative On What’s Next
Bio-IT World | Gregory Simon, President of the Biden Cancer Initiative, discussed the current state of cancer treatment during his keynote address at the 25th annual Molecular Medicine Tri-Conference last week. “What I’m going to talk to you about today,” Simon said, “is changing the way we think about what we’re doing in [cancer] research.”
Feb 23, 2018
-
Share The Data: David Haussler Envisions A New Future For Pediatric Cancer
Bio-IT World | David Haussler, Professor and Scientific Director of the UC Santa Cruz Genomics Institute, came to the 25th annual Molecular Medicine Tri-Conference to discuss using the power of big data to help pediatric cancer patients.
Feb 22, 2018
-
CRISPR In China: Cancer Treatment With Gene Editing Underway
NPR | More than a third of patients with cancer of the esophagus responded to experimental treatment in China with the gene-editing technique CRISPR. Several CRISPR studies are underway there.
Feb 21, 2018
-
100,000 Genomes Project Reaches Halfway Milestone
Bio-IT World Brief | The United Kingdom’s pioneering 100,000 Genomes Project has reached a major milestone by sequencing 50,000 genomes.
Feb 20, 2018
-
Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong.
The New York Times | Scientists are racing to understand why immunotherapy drugs have worked for a few cancer patients when the medicines should have had no effect.
Feb 19, 2018
-
Cambridge Semantics Announces Graph-Based Online Analytics Support For Amazon Neptune, Graph Databases
Bio-IT World Brief | Cambridge Semantics announced a preview of AnzoGraph, a native graph-based parallel query engine available for analyzing data from Amazon Neptune, the new fully managed graph database service from Amazon Web Services.
Feb 16, 2018
-
iRODS Consortium Carries Open Source Data Management Software Forward
Bio-IT World | Integrated Rule-Oriented Data System is used across the globe in industries ranging from the life and physical sciences to media and entertainment. Recent developments in the software have invigorated the life sciences community and provided the possibility of collaboration.
Feb 15, 2018
-
Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug
Forbes | Bristol-Myers Squibb says it will pay a record $1.85 billion to Nektar Therapeutics, a small biotech startup, for rights to its experimental cancer drug, codenamed NKTR-214. Nektar will book 65% of global profits on the drug, should it reach the market, with Bristol getting the other 35%.
Feb 14, 2018
